Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach

被引:112
作者
Ito, K
Kusuhara, H
Sugiyama, Y
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[2] Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan
关键词
oral absorption; CYP3A4; P-glycoprotein; diffusion model; drug interaction;
D O I
10.1023/A:1018872207437
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To evaluate the effects of gut metabolism and efflux on drug absorption by simulation studies using a pharmacokinetic model involving diffusion in epithelial cells. Methods. A pharmacokinetic model for drug absorption was constructed including metabolism by CYP3A4 inside the epithelial cells, P-gp-mediated efflux into the lumen, intracellular diffusion from the luminal side to the basal side, and subsequent permeation through the basal membrane. Partial differential equations were solved to yield an equation for the fraction absorbed from gut to the blood. Effects of inhibition of CYP3A4 and/or P-gp on the fraction absorbed were simulated for a hypothetical substrate for both CYP3A4 and P-gp. Results. The fraction absorbed after oral administration was shown to increase following inhibition of P-gp. This increase was more marked when the efflux clearance of the drug was greater than the sum of the metabolic and absorption clearances and when the intracellular diffusion constant was small. Furthermore, it was demonstrated that the fraction absorbed was synergistically elevated by simultaneous inhibition of both CYP3A4 and P-gp. Conclusions. The analysis using our present diffusion model is expected to allow the prediction of in vivo intestinal drug absorption and related drug interactions from in vitro studies using human intestinal microsomes, gut epithelial cells, CYP3A4-expressed Caco-2 cells, etc.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 31 条
[1]   CORRELATION BETWEEN ORAL-DRUG ABSORPTION IN HUMANS AND APPARENT DRUG PERMEABILITY COEFFICIENTS IN HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS [J].
ARTURSSON, P ;
KARLSSON, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (03) :880-885
[2]   Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes - Major role of CYP3A [J].
Chiba, M ;
Hensleigh, M ;
Lin, JH .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (08) :1187-1195
[3]   Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4 [J].
Crespi, CL ;
Penman, BW ;
Hu, M .
PHARMACEUTICAL RESEARCH, 1996, 13 (11) :1635-1641
[4]  
DEWAZIERS I, 1990, J PHARMACOL EXP THER, V253, P387
[5]   HOW CROWDED IS THE CYTOPLASM [J].
FULTON, AB .
CELL, 1982, 30 (02) :345-347
[6]   THE EFFECTS OF KETOCONAZOLE ON THE INTESTINAL METABOLISM AND BIOAVAILABILITY OF CYCLOSPORINE [J].
GOMEZ, DY ;
WACHER, VJ ;
TOMLANOVICH, SJ ;
HEBERT, MF ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :15-19
[7]   CYCLOSPORIN-ERYTHROMYCIN INTERACTION IN RENAL-TRANSPLANT PATIENTS [J].
GUPTA, SK ;
BAKRAN, A ;
JOHNSON, RWG ;
ROWLAND, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (04) :475-481
[8]   BIOAVAILABILITY OF CYCLOSPORINE WITH CONCOMITANT RIFAMPIN ADMINISTRATION IS MARKEDLY LESS THAN PREDICTED BY HEPATIC ENZYME-INDUCTION [J].
HEBERT, MF ;
ROBERTS, JP ;
PRUEKSARITANONT, T ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (05) :453-457
[9]  
Ito K, 1998, PHARMACOL REV, V50, P387
[10]   Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport [J].
Ito, K ;
Iwatsubo, T ;
Kanamitsu, S ;
Nakajima, Y ;
Sugiyama, Y .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1998, 38 :461-499